-- Due to the pandemic, the Annual General Meeting of Roche Holding Ltd will 
      take place on 16 March 2021 without the physical presence of shareholders 
      and with only the persons required by the Articles of Incorporation in 
      attendance 
 
   -- During the Annual General Meeting, shareholders' rights will be exercised 
      exclusively via the independent proxy, without the physical presence of 
      shareholders 
 
   Basel, 18 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced 
today that unfortunately it will not be possible for shareholders to 
attend the Annual General Meeting in person owing to the ongoing 
pandemic. Our main concern is to protect our shareholders from any 
potential health risks that may arise because of the ongoing difficult 
pandemic situation. 
 
 
 
   As a precautionary and prudent measure, the Board of Directors has 
decided to conduct the Annual General Meeting of Roche Holding Ltd on 
Tuesday, 16 March 2021, in accordance with Art. 8 of the Federal Act on 
the Statutory Principles for Federal Council Ordinances on Combating the 
COVID-19 Epidemic (COVID-19 Act) and Art. 27 of the Ordinance 3 on 
Measures to Combat the Coronavirus (COVID-19) (COVID-19 Ordinance 3) 
without the physical presence of shareholders. The Board of Directors 
regrets having to make this decision, but in view of the current 
situation sees no possibility of holding the General Meeting in the 
usual framework. 
 
 
 
   The Annual General Meeting will therefore be held at the premises of 
Roche Holding Ltd, Grenzacherstrasse 124, 4058 Basel on 16 March 2021 at 
10.30 a.m., with only the persons required by the Articles of 
Incorporation in attendance. 
 
 
 
   Shareholders may exercise their rights exclusively via written or 
electronically submitted instructions to the independent proxy, Testaris 
AG. 
 
 
 
   Further information about the Annual General Meeting and a welcome 
address to shareholders by Dr Christoph Franz, Chairman of the Board of 
Directors, can be found at: 
https://www.globenewswire.com/Tracker?data=x46RK8BVu93EpLAMqTJMZONdzxYoEkYh1FCHftf_I3EsokDh0CQQdPlRNQosq2V5cAWovQs8PQgY9BSDCqpFpK3xmxkxnrXhVzur6pA3yMX7bvHdvcq1_cjhHFUEWgGtrt_M7Wq5B_BkR7umUsivqk_b0_FTuFLyBDb8gpl6L7rSsWR321wsqHw0OBK3LA5Lb7_nC0zk5JaoYtD1Jx3_ew== 
https://www.roche.com/about/governance/annual_general_meetings.htm 
 
 
 
   About Roche 
 
   Roche is a global pioneer in pharmaceuticals and diagnostics focused on 
advancing science to improve people's lives. The combined strengths of 
pharmaceuticals and diagnostics under one roof have made Roche the 
leader in personalised healthcare -- a strategy that aims to fit the 
right treatment to each patient in the best way possible. 
 
 
 
   Roche is the world's largest biotech company, with truly differentiated 
medicines in oncology, immunology, infectious diseases, ophthalmology 
and diseases of the central nervous system. Roche is also the world 
leader in in vitro diagnostics and tissue-based cancer diagnostics, and 
a frontrunner in diabetes management. 
 
 
 
   Founded in 1896, Roche continues to search for better ways to prevent, 
diagnose and treat diseases and make a sustainable contribution to 
society. The company also aims to improve patient access to medical 
innovations by working with all relevant stakeholders. More than thirty 
medicines developed by Roche are included in the World Health 
Organization Model Lists of Essential Medicines, among them life-saving 
antibiotics, antimalarials and cancer medicines. Moreover, for the 
twelfth consecutive year, Roche has been recognised as one of the most 
sustainable companies in the Pharmaceuticals Industry by the Dow Jones 
Sustainability Indices (DJSI). 
 
 
 
   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2019 employed about 98,000 people worldwide. In 
2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 
61.5 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit 
https://www.globenewswire.com/Tracker?data=e990WAN2TsAxZVylVCwvwoa_7qpopPXCCyP0Lae6DMMDdWoDa1ZduUpSqm8J_V5MiP-BbDCX_aZeVzJoLksvEA== 
www.roche.com. 
 
 
 
   All trademarks used or mentioned in this release are protected by law. 
 
 
 
   Roche Group Media Relations 
 
   Phone: +41 61 688 8888 / e-mail: 
https://www.globenewswire.com/Tracker?data=L4CIEel2UbBz7IeVXYW4DGhVGdPBIk516ReamMiofC06yOjd3UMDeQI9j5-boc5Nd0VGtKcE_Gzl9wDkj3O8gn7J2CspyBPZOngzInDwkh6jt7Eoezmn72lKCxK3w08y 
media.relations@roche.com 
 
 
 
 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: +41 61 687 05 17     Phone: +41 61 688 44 86 
Dr. Daniel Grotzky          Karsten Kleine 
 Phone: +41 61 688 31 10     Phone: +41 61 682 28 31 
Nina Mählitz           Nathalie Meetz 
 Phone: +41 79 327 54 74     Phone: +41 61 687 43 05 
Dr. Barbara von Schnurbein 
 Phone: +41 61 687 89 67 
 
 
 
   Attachment 
 
 
   -- 18012021_MR_AGM_EN 
      https://ml-eu.globenewswire.com/Resource/Download/78307621-41da-4c2b-b7e0-ab9486f28587

(END) Dow Jones Newswires

January 18, 2021 01:00 ET (06:00 GMT)